What is Convection Enhanced Delivery?
Drug-device combination therapies utilising convection-enhanced delivery (CED) are an emerging therapeutic strategy for the treatment of neurological disorders. Potent cell and gene therapies (CGTs) have shown efficacy in addressing neurological diseases in animal models, but these findings have yet to be translated into efficacious clinical therapies. A critical factor limiting the use of biologics and chemotherapeutics in the central nervous system is their inability to diffuse across the blood-brain barrier (BBB) and achieve homogeneous distribution within a targeted brain structure. In 1994, scientists discovered that convecting therapies directly into the brain could homogeneously deliver drug to large brain volumes irrespective of the molecular weight of the infused agent. When delivered via CED, the blood-brain barrier becomes advantageous to CGTs and chemotherapies as it acts to retain drugs within the central nervous system thereby reducing systemic immunogenicity and off-target side effects. Outside of the meninges, most of the brain parenchyma has relative immune privilege due to reduced lymphatic drainage and limited presence of activated T-cells. This immune privilege significantly reduces the risk of life-threatening B or T-cell immune responses to viral capsids (AAV) commonly used in gene therapy. At Neurochase, we believe the CNS is the key to unlocking the potential of gene therapies.
patients implanted and infused with a CED drug delivery system
Successful preclinical CED infusions of neurotrophins, chemotherapies or gene therapies.
Total infusion cycles and 5,856 individual catheter infusions completed in GBM, DIPG and Parkinson’s trials.